CN110381935A - 用于识别和减轻个体的认知衰老的ω-3脂肪酸和维生素D水平 - Google Patents

用于识别和减轻个体的认知衰老的ω-3脂肪酸和维生素D水平 Download PDF

Info

Publication number
CN110381935A
CN110381935A CN201780087975.4A CN201780087975A CN110381935A CN 110381935 A CN110381935 A CN 110381935A CN 201780087975 A CN201780087975 A CN 201780087975A CN 110381935 A CN110381935 A CN 110381935A
Authority
CN
China
Prior art keywords
vitamin
individual
omega
fatty acid
homocysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780087975.4A
Other languages
English (en)
Chinese (zh)
Inventor
G·鲍曼
J·L·于德里-拉贝
J·A·J·施密特
C·波沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17193916.8A external-priority patent/EP3388061A1/en
Application filed by Societe des Produits Nestle SA filed Critical Societe des Produits Nestle SA
Priority claimed from PCT/EP2017/082148 external-priority patent/WO2018188771A1/en
Publication of CN110381935A publication Critical patent/CN110381935A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201780087975.4A 2017-04-11 2017-12-11 用于识别和减轻个体的认知衰老的ω-3脂肪酸和维生素D水平 Pending CN110381935A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762484119P 2017-04-11 2017-04-11
US201762484156P 2017-04-11 2017-04-11
US62/484119 2017-04-11
US62/484156 2017-04-11
EP17193916.8 2017-09-29
EP17193916.8A EP3388061A1 (en) 2017-04-11 2017-09-29 Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
US201762580574P 2017-11-02 2017-11-02
US62/580574 2017-11-02
PCT/EP2017/082148 WO2018188771A1 (en) 2017-04-11 2017-12-11 Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals

Publications (1)

Publication Number Publication Date
CN110381935A true CN110381935A (zh) 2019-10-25

Family

ID=67682482

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201780087975.4A Pending CN110381935A (zh) 2017-04-11 2017-12-11 用于识别和减轻个体的认知衰老的ω-3脂肪酸和维生素D水平
CN201880022932.2A Pending CN110475553A (zh) 2017-04-11 2018-04-05 减轻未患痴呆的个体的认知衰老的组合物和方法
CN201880018724.5A Pending CN110430873A (zh) 2017-04-11 2018-04-05 在个体中识别和减弱认知衰老的ω3脂肪酸、同型半胱氨酸和维生素D水平

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201880022932.2A Pending CN110475553A (zh) 2017-04-11 2018-04-05 减轻未患痴呆的个体的认知衰老的组合物和方法
CN201880018724.5A Pending CN110430873A (zh) 2017-04-11 2018-04-05 在个体中识别和减弱认知衰老的ω3脂肪酸、同型半胱氨酸和维生素D水平

Country Status (8)

Country Link
US (6) US20210128587A1 (enExample)
EP (3) EP3609490A1 (enExample)
JP (6) JP7270546B2 (enExample)
CN (3) CN110381935A (enExample)
AU (5) AU2017408873A1 (enExample)
BR (3) BR112019017949A2 (enExample)
CA (3) CA3054846A1 (enExample)
MX (2) MX2019010484A (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7270546B2 (ja) * 2017-04-11 2023-05-10 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 個体における認知的加齢を特定及び軽減するためのオメガ３脂肪酸及びビタミンｄレベル
CN113252806B (zh) * 2021-03-25 2023-08-29 嘉兴学院 S-腺苷同型半胱氨酸在制备用于诊断或治疗川崎病的产品中的用途

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003074A1 (en) * 2000-07-04 2002-01-10 Axis-Shield Asa Diagnostic method for alzheimer's disease based on holo-transcobalamin ii
US20020182196A1 (en) * 2001-04-19 2002-12-05 Mccleary Edward Larry Composition and method for normalizing impaired or deteriorating neurological function
CN101897706A (zh) * 2009-05-27 2010-12-01 北京奥萨医药研究中心有限公司 含有叶酸和b族维生素的组合物及其用途
WO2010143053A1 (en) * 2009-06-10 2010-12-16 Energy4Life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
WO2011143587A1 (en) * 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
WO2014122290A1 (fr) * 2013-02-08 2014-08-14 Centre National De La Recherche Scientifique (Cnrs) Marqueur dyrk1a pour la maladie d'alzheimer
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
US20150086625A1 (en) * 2008-12-31 2015-03-26 Nitromega Corp. Nutraceuticals containing nitro fatty acids
WO2015140545A1 (en) * 2014-03-20 2015-09-24 Isis Innovation Limited Combination therapy comprising an omega-3 fatty acid, a folate species and a vitamin b12 species
WO2016207794A1 (en) * 2015-06-22 2016-12-29 Nestec Sa Compositions and methods for enhancing neurogenesis in animals
WO2017004436A2 (en) * 2015-07-01 2017-01-05 The Regents Of The University Of California A therapeutic system comprising pharmaceuticals in combination with metabolic enhancement for neurodegeneration

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8017657B1 (en) * 2001-09-07 2011-09-13 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
WO2004075905A1 (ja) * 2003-02-26 2004-09-10 Kyowa Hakko Kogyo Co., Ltd. 筋肉増強剤および筋肉減衰の予防または治療剤
US20070078114A1 (en) * 2005-09-02 2007-04-05 Myriad Genetics, Incorporated Combination therapy for alzheimer's disease and other diseases
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
NZ582329A (en) 2007-06-26 2012-09-28 Nutricia Nv Improving memory in subjects with mini-mental state examination of 24-26
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
AU2008307494B2 (en) * 2007-10-04 2013-09-05 Société des Produits Nestlé S.A. Compositions and methods for enhancing cognitive function
CN101909632A (zh) * 2008-01-04 2010-12-08 雀巢产品技术援助有限公司 包含不饱和脂肪酸和一氧化氮释放化合物的组合物及其用于增强认知和相关功能的用途
NZ735173A (en) 2008-12-09 2022-10-28 Stephanie Fryar Williams Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
AU2011315537A1 (en) 2010-10-12 2013-05-02 Vifor Sa Novel omega-3 and omega-6 fatty acid compositions and uses thereof
ES2727043T3 (es) * 2011-03-18 2019-10-11 Nestle Sa Composiciones y métodos útiles para mejorar enfermedades relacionadas con la edad
EP2773339A1 (en) * 2011-10-31 2014-09-10 N.V. Nutricia Composition for improving neuropsychological test battery score
EP2882304A1 (en) * 2012-08-07 2015-06-17 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
AU2014235034A1 (en) 2013-03-15 2015-10-01 Buck Institute For Research On Aging Improved cognitive supplements
EP2899543A1 (en) 2014-01-28 2015-07-29 Predemtec GmbH Biomarker and methods for early diagnosis of Alzheimer's disease
US20180268940A1 (en) * 2015-09-25 2018-09-20 Buck Institute For Research On Aging Compositions and methods for specific biological cognitive functions in neurodegenerative diseases
JP2019518744A (ja) * 2016-05-27 2019-07-04 ネステク ソシエテ アノニム 運動障害を治療又は予防するための栄養組成物
EP3518919A1 (en) * 2016-09-29 2019-08-07 Société des Produits Nestlé S.A. Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
JP7270546B2 (ja) 2017-04-11 2023-05-10 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 個体における認知的加齢を特定及び軽減するためのオメガ３脂肪酸及びビタミンｄレベル

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003074A1 (en) * 2000-07-04 2002-01-10 Axis-Shield Asa Diagnostic method for alzheimer's disease based on holo-transcobalamin ii
US20020182196A1 (en) * 2001-04-19 2002-12-05 Mccleary Edward Larry Composition and method for normalizing impaired or deteriorating neurological function
US20150086625A1 (en) * 2008-12-31 2015-03-26 Nitromega Corp. Nutraceuticals containing nitro fatty acids
CN101897706A (zh) * 2009-05-27 2010-12-01 北京奥萨医药研究中心有限公司 含有叶酸和b族维生素的组合物及其用途
WO2010143053A1 (en) * 2009-06-10 2010-12-16 Energy4Life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
WO2011143587A1 (en) * 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
WO2014122290A1 (fr) * 2013-02-08 2014-08-14 Centre National De La Recherche Scientifique (Cnrs) Marqueur dyrk1a pour la maladie d'alzheimer
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
WO2015140545A1 (en) * 2014-03-20 2015-09-24 Isis Innovation Limited Combination therapy comprising an omega-3 fatty acid, a folate species and a vitamin b12 species
WO2016207794A1 (en) * 2015-06-22 2016-12-29 Nestec Sa Compositions and methods for enhancing neurogenesis in animals
WO2017004436A2 (en) * 2015-07-01 2017-01-05 The Regents Of The University Of California A therapeutic system comprising pharmaceuticals in combination with metabolic enhancement for neurodegeneration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENE BOWMAN等: "Nutrient biomarker patterns and cognitive decline in older adults (124.6)", THE FASEB JOURNAL, vol. 28, no. 1, pages 1 - 2 *
P BARBERGER-GATEAU: "Nutrition and brain aging: how can we move ahead?", EUROPEAN JOURNAL OF CLINICAL NUTRITION, vol. 68, no. 11, pages 1245 - 1249, XP037762381, DOI: 10.1038/ejcn.2014.177 *

Also Published As

Publication number Publication date
AU2025220690A1 (en) 2025-09-04
US20200054665A1 (en) 2020-02-20
US20210128587A1 (en) 2021-05-06
JP7434459B2 (ja) 2024-02-20
JP2022172152A (ja) 2022-11-15
EP3609490A1 (en) 2020-02-19
CA3054869A1 (en) 2018-10-18
CN110430873A (zh) 2019-11-08
JP2022166175A (ja) 2022-11-01
EP3609491B1 (en) 2025-11-05
US20210263048A1 (en) 2021-08-26
MX2019010828A (es) 2019-10-15
JP7270547B2 (ja) 2023-05-10
EP3609487A1 (en) 2020-02-19
JP2023030130A (ja) 2023-03-07
BR112019017949A2 (pt) 2020-05-19
US20230310488A1 (en) 2023-10-05
CA3054864A1 (en) 2018-10-18
MX2019010484A (es) 2019-10-17
AU2024200882B2 (en) 2025-07-24
EP3609491A2 (en) 2020-02-19
AU2018251092A1 (en) 2019-09-05
JP7524294B2 (ja) 2024-07-29
CN110475553A (zh) 2019-11-19
US20230028607A1 (en) 2023-01-26
BR112019018729A2 (pt) 2020-04-07
JP2020516862A (ja) 2020-06-11
JP2020516586A (ja) 2020-06-11
CA3054846A1 (en) 2018-10-18
AU2018251094B2 (en) 2023-11-02
AU2024200882A1 (en) 2024-02-29
AU2018251092B2 (en) 2024-02-29
JP7270546B2 (ja) 2023-05-10
AU2017408873A1 (en) 2019-08-29
AU2024200882B9 (en) 2025-11-20
AU2018251094A1 (en) 2019-09-05
BR112019020008A2 (pt) 2020-04-28
US20240041915A1 (en) 2024-02-08
JP7434458B2 (ja) 2024-02-20
JP2020516864A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
US20240041915A1 (en) Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
Bowman et al. A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial
US10821130B2 (en) Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia
Ruusunen Diet and depression: an epidemiological study
Freedman et al. Prenatal choline and the development of schizophrenia
US20230226097A1 (en) Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability
Hadidi The Role of Diet in Male Veterans with Multiple Sclerosis
James 23rd Marabou Symposium: Nutrition and the Aging Brain
Halili The effects of ketogenic diets and ketosis on cognition in Alzheimer's disease
Bergmans et al. The association of dietary inflammatory potential with depression and mental well-being among US
How Can et al. ORTHOMOLECULAR TREATMENT FOR SCHIZOPHRENIA: A REVIEW (PART ONE)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191025